SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Ongoing Investigation of Claims Against PTC Therapeutics, Inc. And Strongly Encourages Investors With Losses To Contact The Firm

IRVINE, Calif.--()--Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by PTC Therapeutics, Inc. (“PTC” or the “Company”) (Nasdaq: PTCT). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased shares of PTC during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on a Refuse to File letter the U.S. Food and Drug Administration (FDA) sent to the Company concerning its new drug Translarna. The FDA stated that the Company had not submitted an application complete enough to review.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com